EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

TRPV4 controls circadian and pathological ocular hypertension

Sarah N Redmon, Monika Lakk iD, Yun-Ting Tseng iD, Christopher N Rudzitis, Jordan E Searle iD, Feryan Ahmed, Andrea M Unser, Teresa Borrás iD, Karen Torrejon, David Križaj iD

The Journal of Physiology · 2025

DOI: 10.1113/jp288706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Physiology, 2025. Verfasst von Sarah N Redmon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology & Visual Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA. Hauptthemen laut MEDLINE: TRPV Cation Channels, Ocular Hypertension, Circadian Rhythm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NEI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ocular hypertension (OHT) caused by mechanical stress and chronic glucocorticoid exposure reduces the hydraulic permeability of the conventional outflow pathway and increases the risk for irreversible vision loss, yet healthy individuals experience nightly intraocular pressure (IOP) elevations without adverse lifetime effects. It is not known how mechanosensation regulates physiological vs . pathological OHT nor how it impacts permeability of the principal drainage pathway through the trabecular meshwork (TM). We report that OHT induced by the circadian rhythm, occlusion of the iridocorneal angle and glucocorticoids requires activation of transient receptor potential vanilloid isoform 4 (TRPV4), a stretch‐activated cation channel. Wild‐type mice responded to nocturnal topical administration of the agonist GSK1016790A with IOP lowering, whereas intracameral injection of the agonist elevated diurnal IOP. Microinjection of TRPV4 antagonists HC‐067047 and GSK2193874 lowered IOP during the nocturnal OHT phase and in hypertensive eyes treated with dexamethasone or injection of polystyrene microbeads. Conventional outflow‐specific Trpv4 knockdown induced partial IOP lowering in mice with an occluded iridocorneal angle and protected retinal neurons from pressure injury. Indicating a central role for TRPV4‐dependent mechanosensing in trabecular outflow, HC‐067047 doubled the outflow facility in TM‐populated steroid‐treated 3‐D nanoscaffolds. Tonic TRPV4 signalling thus represents a fundamental property of TM biology as a driver of increased in vitro and in vivo outflow resistance. The TRPV4 dependence of OHT under conditions that mimic primary and secondary glaucomas could be explored as a novel target for glaucoma treatments. image Key points Transient receptor potential vanilloid isoform 4 (TRPV4), a stretch‐activated channel, is required to maintain ocular hypertension (OHT) under physiological and pathological conditions. Intraocular pressure elevations induced by occlusion of the iridocorneal angle, administration of steroid eye drops and circadian rhythmicity were blocked by TRPV4 antagonists and mimicked with a TRPV4 agonist. TRPV4 inhibition suppressed steroid‐induced increases in outflow resistance in an in vitro biomimetic model of trabecular outflow. Conditional ablation of TRPV4 channels from the trabecular meshwork prevented the induction of OHT and protected the eye from glaucoma. These findings bring physiological and pathological mechanisms that mediate OHT into mechanobiological context and identify a novel target for pressure control in glaucoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TRPV Cation ChannelsOcular HypertensionCircadian RhythmAnimalsIntraocular PressureMiceTrabecular MeshworkMice, Inbred C57BLMaleSulfonamidesLeucineMorpholinesPiperidinesPyrrolesQuinolines

Stichwörter der Autor:innen

IOP‐lowering therapyTRPV4circadian rhythmeyeglaucomaintraocular pressuretrabecular meshwork

Substanzen

TRPV Cation ChannelsTrpv4 protein, mouseN-(1-((4-(2-(((2,4-dichlorophenyl)sulfonyl)amino)-3-hydroxypropanoyl)-1-piperazinyl)carbonyl)-3-methylbutyl)-1-benzothi…HC-067047SulfonamidesLeucineGSK2193874MorpholinesPiperidinesPyrroles

Autor:innen und Institutionen

  • Department of Ophthalmology & Visual Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA.
  • Humonix Biosciences, Albany, NY, USA.
  • Department of Ophthalmology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • Department of Neurobiology, University of Utah, Salt Lake City, UT, USA.
  • Department of Bioengineering, University of Utah, Salt Lake City, UT, USA.

ORCID-Profile: Monika Lakk, Yun-Ting Tseng, Jordan E Searle, Teresa Borrás, David Križaj

Förderung

  • NEI NIH HHS

Zitieren

APA

Redmon, S. N., Lakk, M., Tseng, Y. T., Rudzitis, C. N., Searle, J. E., Ahmed, F., Unser, A. M., Borrás, T., Torrejon, K., & Križaj, D. (2025). TRPV4 controls circadian and pathological ocular hypertension. The Journal of Physiology. https://doi.org/10.1113/jp288706

Vancouver

Redmon SN, Lakk M, Tseng YT, Rudzitis CN, Searle JE, Ahmed F, et al. TRPV4 controls circadian and pathological ocular hypertension. The Journal of Physiology. 2025. doi:10.1113/jp288706

BibTeX
@article{Redmon2025,
  author = {Redmon, Sarah N and Lakk, Monika and Tseng, Yun-Ting and Rudzitis, Christopher N and Searle, Jordan E and Ahmed, Feryan and Unser, Andrea M and Borrás, Teresa and Torrejon, Karen and Križaj, David},
  title = {TRPV4 controls circadian and pathological ocular hypertension},
  journal = {The Journal of Physiology},
  year = {2025},
  doi = {10.1113/jp288706}
}
Kostenlos starten →